SCYNEXIS, Inc. Deferred Costs, Current
SCYNEXIS, Inc. (SCYX) had Deferred Costs, Current of $533.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredCostsCurrent · last filed 2026-08-10
- 2026-06-30: Deferred Costs, Current $533.00K.
- 2026-03-31: Deferred Costs, Current $2.43M.
- 2025-12-31: Deferred Costs, Current $0.00.
| Period end | Deferred Costs, Current |
|---|---|
| 2026-06-30 | $533.00K 10-Q · filed 2026-08-10 |
| 2026-03-31 | $2.43M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |